1. Introduction
===============

The protozoan parasite *Theileria parva* is transmitted by *Rhipicephalus* ticks and causes an often fatal lymphoproliferative disease of cattle known as East Coast fever (ECF). In keeping with the distribution of its principal vectors, *Rhipicephalus appendiculatus* and *R. zambeziensis*, the disease is prevalent in eastern, central and southern Africa ([@bib11]), where an estimated 24 million cattle are at risk of infection. Economic losses due to ECF are substantial, as evidenced by a 1989 analysis that placed them at US\$168 ([@bib17]). Efforts to control ECF are largely based on the use of acaricides to prevent infestation with infected ticks, but this approach is increasingly being compromised by the emergence of acaricide resistance in the vector tick populations. Although drugs are available to treat the disease, these are expensive and require an early diagnosis to be effective. It is also possible to immunise cattle against *T. parva* by inoculation with live parasites in combination with long acting formulations of oxytetracycline. This so-called infection and treatment method ([@bib24; @bib25]) is effective, but its uptake has been hampered by cold chain difficulties and concerns that vaccine strains might establish in resident tick populations and mix with local parasite genotypes ([@bib21]).

The parasite has a complex life cycle ([@bib14]), involving obligate developmental stages in mammalian and vector hosts. Cattle become infected by inoculation of sporozoite forms in the tick saliva. These invade lymphocytes and differentiate to multinucleate schizonts, which drive the cell into a state of continuous proliferation and divide with it, ensuring transmission of infection to each daughter cell. In a proportion of infected cells, schizonts undergo further differentiation to uninucleate merozoites; these are released from the dying cell and invade erythrocytes, where they develop into tick-infective piroplasm forms. Upon ingestion by a feeding tick, these are released into the gut lumen and give rise to macro and micro gametes, which undergo syngamy to form diploid zygotes. After invading gut epithelial cells, zygotes undergo reduction division to yield kinete forms, which access the hemocoel and migrate to the salivary gland, where they invade cells of type III acini. The parasite then undergoes a process of sporogony to produce cattle-infective sporozoites. The parasite therefore adopts a strategy whereby expansion is accomplished through asexual division, with an exponential phase in the case of the schizont, while genetic exchange is accommodated through a sexual phase in the tick ([@bib18]).

Early observations of limited cross-protection among field isolates of *T. parva* prompted a strong interest in the diversity of the parasite. This led to the generation of monoclonal antibodies that could distinguish between different parasite isolates ([@bib15; @bib5]). The advent of DNA-based technologies gave rise to the development of a series of new markers that could distinguish multiple genotypes simultaneously. The first of these were Southern blot-based and used combinations of restriction enzymes and probes for the small subunit ribosomal RNA gene as well as probes for multi-copy genes from the TpR and sub telomeric loci ([@bib3]). These markers showed extensive polymorphism between isolates but the results of mixed infections were more difficult to interpret. PCR-RFLPs of the 18S ribosomal RNA locus, Polymorphic Immunodominant Molecule (PIM) PCR amplicon size polymorphisms and PIM sequence analysis were also used to distinguish different isolates and stocks ([@bib1; @bib7]). However, the availability of the *T. parva* genome allowed the identification of satellite sequences comprising multiple nucleotide repeats, which, because of varying numbers of repeats, give rise to alleles with distinct PCR amplicon sizes. Satellite markers have provided insights into the genetic relationship between *T. parva* populations ([@bib23; @bib10]) and the population dynamics and sub-structuring of field isolates ([@bib20; @bib19]). They have also been applied to elucidate the impact of immune selection on the parasite ([@bib9]) and the risks associated with the infection and treatment method ([@bib22; @bib21]). At a more practical level, the source of a recent outbreak of ECF on the Comoros Islands was traced to an infection and treatment vaccine used in cattle exported from Tanzania using microsatellite profiling ([@bib6]).

Although many polymorphic markers now exist for the distinction of different *T. parva* genotypes, large regions of its genome remain for which no markers are available. Effective evaluation of recombination rates and genotypic variation in response to selection pressure requires a genome-wide set of markers with good coverage. We therefore undertook to develop additional satellite and PCR-RFLP markers to get a better genome-wide coverage.

2. Materials and methods
========================

2.1. Parasite material
----------------------

The study focused on the Marikebuni stock of *T. parva*, which was initially isolated in 1981 in the Kilifi District in Kenya ([@bib15]). It underwent three cattle--tick passages at the International Livestock Research Institute (ILRI) in Nairobi to yield ILRI St3014 ([@bib16]). This stabilate was passaged again at the National Veterinary Research Centre, NVRC, in Kenya and infected ticks were sent to the Centre for Tropical Veterinary Medicine, University of Edinburgh. These were used to generate stabilate CTVM St70, which has since been passaged twice to generate stabilates CTVM St72 and CTVM St96. The history of the *T. parva* Muguga stabilate CTVM-ST80 is less well defined. This isolate was maintained for many years by serial cattle--tick passage and underwent several further cattle--tick passages after importation into the UK.

2.2. Animal immunisation, challenge and stabilate production
------------------------------------------------------------

A Friesian calf was infected by subcutaneous inoculation with 1 × 10^7^ autologous cells infected with the 72-01 genotype of *T. parva* Marikebuni (see below). The animal showed only mild clinical signs and recovered without treatment. The immune status of the calf was confirmed by detection of *in vitro* MHC-restricted CTL activity against the immunising cell line as described by [@bib8]. The animal was challenged two months after the initial infection with a lethal dose of the parent stabilate CTVM St72 by subcutaneous inoculation above the right prescapular lymph node. Progress of infection was followed by monitoring rectal temperature and examining lymph node biopsy and blood smears for the presence of schizonts and piroplasms respectively. Unfed nymphal *R. appendiculatus* ticks were applied to the ears of the calf from day 10 of challenge to allow passage of the break-through infection and production of a daughter stabilate. The level of infection in the resulting tick batch was assessed by examination of salivary glands from a representative sample as described by [@bib27] and stabilate CTVM St105 was prepared from it as described by [@bib4].

2.3. Generation of parasite clones and lysis for PCR
----------------------------------------------------

Parasite clones for genotyping were generated by limiting dilution cloning of PBMCs infected *in vitro* with *T. parva* sporozoite stabilates or lymph node aspirates obtained from an infected animal as described by [@bib26]. Parasite clones were grown in 96 well plates, harvested and lysed, by incubation for 10 h at 56 °C in culture medium containing 50 μg/ml Proteinase K. PCR reactions were conducted directly on the lysates after heating to 90 °C for 10 min to inactivate Proteinase K.

2.4. Polymorphic markers and genotyping
---------------------------------------

(i)*PCR-RFLPs*: Comparative analysis of the genomic sequences of *T. annulata* and *T. parva* ([http://www.sanger.ac.uk](http://www.sanger.ac.uk/) and [http://www.tigr.org](http://www.tigr.org/) respectively) was undertaken to identify genes that are polymorphic between the two species. Polymorphic coding regions that differed in size between the species were selected and primer pairs flanking the most variable segments were designed to amplify products ranging from 600 bp to 1800 bp. PCR amplicons generated from *T. parva* Muguga and Marikebuni clones using these primers were digested with a panel of 10 frequent cutting restriction enzymes (AluI, DpnII, HaeIII, HhaI, HinfI, MseI, MspI, RsaI, TaqI and Tsp509I) to identify RFLPs. Details of the polymorphic PCR-RFLP markers are shown in [Table 1](#tbl1){ref-type="table"}.(ii)*Satellite markers*: The satellite markers ms1--ms11, MS1--MS46, MS221a, MS221b, MS312, MS717 and MS817 have been published previously by [@bib23] and markers MS47--MS59 have been described by [@bib10]. The repeat finder program ([@bib2]) was used as described by [@bib23] to identify 35 additional satellite loci on chromosomes 1 and 2 for testing.(iii)*Size polymorphisms*: In addition to the 4 previously described genes that show PCR size polymorphisms among *T. parva* isolates ([@bib10]), one new marker, TP02-0895, was identified on chromosome 2 with size variants detectable by PCR (forward primer gcctgtcaagagtaccttaatgcc, reverse primer gaccgcttggctgacctggacc).(iv)*PCR conditions and genotyping*: PCR conditions used in the study were essentially as described by [@bib23], except that the number of cycles was increased to 40, Bioline (UK) taq polymerase was used and a custom made 10× PCR buffer (45 mM Tris--HCl (pH 8.8), 11 mM (NH~4~)~2~SO~4~, 4.5 mM MgCl~2~, 0.113 mg/ml BSA, 4.4 μM EDTA, 1.0 mM each of dATP, dCTP, dGTP and dTTP) was purchased from ABgene (UK). PCR products were separated on 2% Metasieve agarose (Flowgen, UK), visualised with ethidium bromide and photographed using a UV light box (BioRad, UK).

3. Results
==========

3.1. Genetic tools to study *T. parva*
--------------------------------------

Comparison of the *T. annulata* and *T. parva* genomes led to the identification of 105 open reading frames that exhibited sequence variation or gaps in the sequence alignment and these were used to design *T. parva*-specific primers flanking the polymorphic regions. Digestion of PCR products, obtained from *T. parva* Muguga and Marikebuni clones with these primers, with a panel of 10 restriction enzymes led to the identification of 42 PCR-RFLPs, 3 of which are shown in [Fig. 1](#fig1){ref-type="fig"}. A list of all PCR-RFLPS, along with their primer sequences, relevant restriction enzyme and location in the *T. parva* genome are shown in [Table 1](#tbl1){ref-type="table"}. Large sections of chromosomes 1 and 2 were devoid of satellite markers and these regions were therefore re-examined using the repeat finder program ([@bib2]) in an attempt to identify more markers in those regions. As a result, 36 further primer pairs were designed and tested with DNA from *T. parva* Muguga and Marikebuni clones and 19 of these markers were found to be polymorphic, 3 of which are shown in [Fig. 1](#fig1){ref-type="fig"}. The names, primer sequences and Muguga amplicon sizes of these polymorphic satellite markers are shown in [Table 2](#tbl2){ref-type="table"}. An illustration of the locations of all new and previously identified satellite markers and newly identified PCR-RFLP markers are shown in [Fig. 2](#fig2){ref-type="fig"}. The figure shows the location of all 94 polymorphic satellite markers, 42 PCR-RFLPs and the 5 genes which exhibit amplicon size polymorphisms. Of these markers, 43, 34, 35 and 29 markers locate on chromosome 1, 2, 3 and 4, respectively. Of the 29 markers on chromosome 4, 12 are tightly clustered into two groups, separated by a stretch of over 772 kb that lacks any polymorphic satellite markers. This stretch contains only 2 polymorphic PCR-RFLP markers, leaving chromosome 4 with the largest stretch for which polymorphic markers are unavailable.

3.2. Parasite population structure changes during cattle--tick passage
----------------------------------------------------------------------

PCR analysis of DNA extracted from *T. parva* Marikebuni stabilates derived from four serial cattle--tick passages (ILRI St3014--CTVM St70--CTVM St72--CTVM St96) with a panel of satellite markers revealed that individual passages can lead to marked changes in population structure. Representative results using the MS14 satellite marker are illustrated in [Fig. 3](#fig3){ref-type="fig"} and show that, while ILRI 3014 is dominated by one allele of this marker, its passage to CTVM 70 was associated with the emergence of at least two additional alleles. After further passage to CTVM St72, one of these new alleles has become dominant, while the original ILRI 3014 allele is indiscernible. This genotypic profile was retained after an additional passage of the stock to yield CTVM St96. Multi locus genotyping (MLG) of clones obtained from CTVM St72 and St96 with a panel of 69 satellite markers, as well as 5 PCR size polymorphisms and 3 PCR-RFLPs, confirmed that both stabilates are dominated by the same genotype (72-01). Of 287 clones obtained from stabilate CTVM St72, 218 (76%) carried the 72-01 genotype, while most of the remaining 69 clones were singletons. Similarly, the 72-01 genotype accounted for 76.2% of clones analysed from CTVM 96 and the frequency of 72-01 alleles carried by the remainder was higher than that observed in CTVM St72.

3.3. Evidence of immune selection
---------------------------------

The impact of the bovine immune response on the progression of *T. parva* infection was studied by challenging a calf immunised against the 72-01 genotype with the parent stabilate CTVM St72. The immune status of the calf was confirmed prior to challenge by detection of parasite-specific CTL *in vitro*. The animal developed mild clinical signs following challenge, with transient fever and emergence of both schizonts and piroplasms, and recovered without treatment. Ticks fed on the animal following challenge exhibited low infection rates but were used to generate a working stabilate, CTVM St105. Parasite clones were obtained from lymph node aspirates collected on days 9 (*n* = 34) and 14 (*n* = 27) of the challenge infection and from cloned parasitized cell lines derived by *in vitro* infection with CTVM St105 (*n* = 75). MLG analysis of the ex vivo-derived clones with a subset of 69 polymorphic markers, including 5 genes with PCR size polymorphisms, revealed only 7 occurrences of the 72-01 genotype at day 9. The genotype was not detected among the day 14 clones or those generated *in vitro* using the CTVM St105 stabilate. A significant reduction in the prevalence of the 72-01 genotype was also apparent in DNA amplified from serial lymph node aspirates and erythrocyte theileriosis fractions collected during the challenge infection. This is illustrated in [Fig. 4](#fig4){ref-type="fig"} using the polymorphic marker MS27, which is representative of several markers for both non-coding and coding regions ([Fig. 4](#fig4){ref-type="fig"}). In addition, the 72-10 alleles of four expressed genes (TP01-0966, TP01-1233, TP03-0681, TP04-0051) were absent from over 82% of the parasite clones analysed from the breakthrough stabilate CTVM-St105 (data not shown).

4. Discussion
=============

We describe an expanded set of molecular markers for the study of population diversity in *T. parva* parasites. The panel now comprises 141 PCR based markers that are distributed across the genome as depicted in [Fig. 2](#fig2){ref-type="fig"}, which shows revised position for previously published satellite markers on chromosome 3 ([@bib23]). The markers are not evenly distributed, but instead often cluster together in certain regions of the four chromosomes. Attempts to identify markers in gaps have met with only limited success, suggesting that the regions that lack polymorphic markers may represent regions in which the *T. parva* genome is conserved across different isolates. Alternatively, they may simply reflect conservation between the Muguga and Marikebuni isolates in these regions of the genome. It is therefore possible that testing markers that failed to reveal polymorphisms in this study might do so if tested on a broader range of isolates. This might reveal more markers for chromosome 4 and provide a sufficient marker density to support an approach for strain specific antigen identification similar to that adopted by [@bib12] in their genetic approach to mapping targets of strain specific immunity in malaria.

These genetic tools have allowed us to evaluate parasite diversity in both distinct and related *T. parva* stabilates. Analysis of the *T. parva* Muguga stabilate CTVM St80 has shown that the stabilate is almost clonal (data not shown); out of 48 clones analysed 45 were identical and only 4 multi locus genotypes were observed. These were distinguished by differences at only 3 satellite loci. In the case of one locus, one of the observed alleles was novel, while the other 2 had been seen before in Marikebuni clones. The novel allele may have arisen through spontaneous mutation within the Muguga stabilate. Alternatively, this and the other 2 alleles may reflect true diversity that has survived many cattle to tick passages and remain the only examples of polymorphism left from the original Muguga isolate.

The observation of a total of 70 genotypes within the CTVM St72 was surprising as analysis of bulk stabilate DNA with individual markers suggested the presence of a dominant genotype along with, possibly, one or two others. This level of diversity, coupled with the substantial changes observed after a single cattle--tick passage, has important implications for the design of experiments that rely on *T. parva* stabilates. Workers in the past have assumed that the genetic composition of heterogeneous stabilates is relatively stable.

This has important implications for maintenance of the "Muguga cocktail", which forms the basis of infection and treatment immunisation in eastern Africa. Comprising three heterogeneous stocks -- Muguga, Kiambu 5 and Serengeti transformed -- there is clearly a danger that repeated passage will result in changes in the antigenic composition of the cocktail. The molecular typing reagents described in this paper provide a valuable tool to characterise the individual components of the "Muguga cocktail" and, possibly, to identify which genotype or genotype-combinations are essential to confer protection against natural field challenge. The identification of the protective components will be essential for quality assurance of the next generation of the "Muguga cocktail".

The underlying cause of the observed changes in parasite composition of successive *T. parva* Marikebuni stabilates remains unclear. The history of these stabilates has shown that three tick lines were used to propagate the parasite during the course of these passages, which occurred at ILRI, NVRC Muguga and the CTVM. Hence, ILRI ticks were used to generate ILRI St3014, CTVM St70 arose from the tick colony at the NVRC and CTVM St72 and St96 were generated with ticks from the CTVM colony. Another possible reason for these changes is that distinct cattle breeds were used at each stage---Boran cattle were used at ILRI, the NVRC used a Boran-Friesian cross and Friesian calves were used at the CTVM. Alternatively, the emergence of dominant genotypes or changes of genotype composition may simply be stochastic, representing a chance event in which a given parasite genotype manages to establish initially a more vigorous infection in the bovine host and thereby subsequently dominates the infection in the tick host.

Immunisation with the 72-01 genotype followed by challenge with CTVM St72, in which the 72-01 genotype accounts for 76% of the parasite population, has shown that while the bovine immune response can clear the immunising parasite genotype during the challenge infection, other genotypes can persist and be transmitted to feeding ticks. This is in line with the reported tight focus of the CTL response (see [@bib13]). This has very important implications for the sustained use of a given infection and treatment vaccine in the same geographical area. It may lead to the selection of local parasite strains, which are antigenicly distinct from the vaccine components, which, in time would result in failure of the vaccine.
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![Examples of polymorphic markers identified in this study. (A) PCR-RFLP markers with corresponding restriction enzyme. (B) Newly identified satellite markers. (C) TP02-0895 a newly discovered gene with amplicon size polymorphism. Lane 1, Muguga clone 273; lane 2, Marikebuni clone 3219.](gr1){#fig1}

![Graphical illustration of the locations of polymorphic markers in the *T. parva* genome. Chromosomes 1--4 are denoted by I--IV. Genes with amplicon size polymorphism and satellite marker loci are shown on the left hand side of each chromosomes, while PCR-RFLP locations are shown on the right. Sizes of individual chromosomes are identified below.](gr2){#fig2}

![Satellite analysis of whole genomic DNA extracted from four successive generations of the *T. parva* Marikebuni isolate using marker MS14. Lane 1, ILRI St3014; lane 2, CTVM St70; lane 3, CTVM St72; lane 4, CTVM St96. The arrows mark amplicon sizes in base pairs.](gr3){#fig3}

![Clearance of the immunising parasite genotype 72-01 in lymph node and erythrocyte compartments on the indicated days after challenge with stabilate CTVM St72 as revealed by PCR amplification with satellite marker MS27. The arrowheads denote the allele carried by the immunising genotype 72-01. The arrows mark amplicon sizes in base pairs.](gr4){#fig4}

###### 

PCR-RFLP marker loci identified in this study[a](#tbl1fn1){ref-type="table-fn"}.

  Marker Name   Forward Primer                Reverse Primer                Restriction Enzyme   Chromosome No.   Position   Amplicon Size
  ------------- ----------------------------- ----------------------------- -------------------- ---------------- ---------- ---------------
  PCR-RFLP 01   acagggatgattctggtaattttt      tggktggcataagtamtctgtgat      RsaI                 1                31359      698
  PCR-RFLP 02   amcgcaraatatyaaaacagaact      tttttgacctacttaaatcatttgaca   RsaI                 1                83497      928
  PCR-RFLP 03   ccakgagaaccttaacactgmctc      agtcaagtttcrtcttcgtttcct      MspI                 1                224219     682
  PCR-RFLP 04   ttgttaataccacsccaattatca      aggktcyaaatactttcccaaaa       TaqI                 1                340696     694
  PCR-RFLP 05   ygacgaagataatatggayatgga      ctccatacagtgctctcgttacat      RsaI                 1                449608     1555
  PCR-RFLP 06   cacaaggagagttatttgcgtct       tcctyttcatcatcttctcraaca      TaqI                 1                562140     642
  PCR-RFLP 07   attgacgttctcaaaattggtgat      tccatttttgaagccatttttatt      HinfI                1                1254876    625
  PCR-RFLP 08   tgttctttttatttggactcttttcc    ttggtcttctgctgtgtaagaagt      HinfI                1                2040407    1564
  PCR-RFLP 09   gataagttgttacgcacatgggtt      atttggatcgctaactagtctgc       RsaI                 1                2180754    923
  PCR-RFLP 10   tacttggtgcaatttctagtctcg      ggcgagttgtggtaaatctca         RsaI                 1                2333508    1435
  PCR-RFLP 11   accgggtttcagaaagtttttaat      gcgaggaaattgatgagaagtagt      TaqI                 1                2430398    1138
  PCR-RFLP 12   ctttgagaaatggctcaatgagta      tgcagaggagagtgttaggatara      RsaI                 2                145250     1202
  PCR-RFLP 13   ctaggagttaacccaggaacmag       ctgatttggacttcgattcytttt      TaqI                 2                246693     1644
  PCR-RFLP 14   ttcgcaaatttaccaaagttttta      tcatccaagggttaattttcctaa      MspI                 2                328448     1566
  PCR-RFLP 15   gtgacacatttaaccccaactatg      cgtgtttaacctccatcctcttta      MspI                 2                610294     992
  PCR-RFLP 16   ttggaccatggatttaaagagttt      gataaattcaagcaaatcaaccaa      MseI                 2                663512     848
  PCR-RFLP 17   ggtaaacctttaggtgtgtttgga      tgccaaataatcctccagtagtag      AluI                 2                712657     1021
  PCR-RFLP 18   gagagtgattttggagaaggctac      gactcaaccttcttcgctactctc      MspI                 2                712864     1715
  PCR-RFLP 19   gaaaaatgccgaaaaataaagg        atcgaaatccgactcctcttg         MseI                 2                1541106    695
  PCR-RFLP 20   ttcattgttaccaccaaatcttc       cgacactttccacatcgttacata      HaeIII               2                1563675    1224
  PCR-RFLP 21   ggatatgataaagattggtataaatgg   tcacagttaaatcaacagctgctac     TaqI                 2                1740543    742
  PCR-RFLP 22   taaaccacaaggagctcttcctac      aacgacgccttaaactttctatac      HinfI                2                1760832    1401
  PCR-RFLP 23   gaayggattwagatttgatgtggt      atttmccagattccattraataaa      HhaI                 2                1797638    847
  PCR-RFLP 24   tctgaacgacttgcagtatgacta      gactccaacacaacgaattca         HhaI                 3                83833      695
  PCR-RFLP 25   ggtatttaagggtagaattggagg      tttccataaaggatcaatattctcaa    MseI                 3                157770     781
  PCR-RFLP 26   ttctgatcccctgatacaattttt      ttatgttaccgcaatcaccaatag      HinfI                3                237629     1426
  PCR-RFLP 27   tgaagcctgtcaagttgcttta        tgcgttacatacacttcccttg        AluI                 3                426084     1783
  PCR-RFLP 28   aagaacactcagttatgaaggctgt     ccctcatcttaccactcaatttct      HaeIII               3                451885     841
  PCR-RFLP 29   ccagctgtatactcacttgttgct      aacttgttttcctttggcttagg       AluI                 3                741856     968
  PCR-RFLP 30   acggtttatgacaagtctgtacca      tcgaacgagtgttttaactttttg      RsaI                 3                841803     1198
  PCR-RFLP 31   tgagttatttgaggaaggatttgag     ttttaaagagtcccaagtgttcaa      HhaI                 3                842942     766
  PCR-RFLP 32   cacgtatgtatcccaagtatccac      gaggatttgagaacccagttacc       MseI                 3                871672     1100
  PCR-RFLP 33   tgcttaaaggctcagttatcacaa      acaaattcgggtatgtttttgaa       RsaI                 3                1051310    973
  PCR-RFLP 34   gaaaaactgctcaaactccgttat      aaagtactcgtggtctggagtctg      AluI                 3                1054808    1119
  PCR-RFLP 35   atctcaaatggctttgctaaactt      gcaaataatattgcagataccagaa     MseI                 3                1761447    908
  PCR-RFLP 36   tatatacacttcckgtwrtcggta      gttcatcgtttttcccataaaca       MseI                 3                1843437    1469
  PCR-RFLP 37   ttcatattattcggatctgtgaga      tctccgtcacatactacttgttca      HaeIII               4                10450      1555
  PCR-RFLP 38   cagtctcaacaattgggacagata      gtaacttctccttcatttccttgg      RsaI                 4                265377     1123
  PCR-RFLP 39   tccataggtattctcgaaggtct       gtgttcctatctcaccctccaac       MseI                 4                327090     777
  PCR-RFLP 40   gacgctagactacgatgaaatgaa      gtgcactctcaaacgcctaakmat      Tsp509I              4                787561     630
  PCR-RFLP 41   gggaacacaaaccaagcaag          atctgcctcagtgccttcat          AluI                 4                869417     922
  PCR-RFLP 42   cgttgtaggcttaatgatgaactt      catcattgattttagcggtgaat       RsaI                 4                1124923    1142

The amplicon sizes shown are those found in the *T. parva* Muguga clone 3308 ([http://www.tigr.org](http://www.tigr.org/)).

###### 

New satellite marker loci identified in this study[a](#tbl2fn1){ref-type="table-fn"}.

  Marker Name   Forward Primer          Reverse Primer            Chromosome No.   Position   Amplicon Size
  ------------- ----------------------- ------------------------- ---------------- ---------- ---------------
  MS60          aatctgagggtcaaaggatt    tcaatcaacatgttatcagga     1                1565       352
  MS61          gaagagggtactgaagctga    aggatcagtagctggagttg      1                392663     248
  MS62          gcaaaatcgaactaccacat    cgctctagcctctgtaacac      1                599307     271
  MS63          tcattccatcggatctttat    tggtaaaacttcgtaaaaagg     1                655871     263
  MS64          acatccttaggcacaacatc    gctgcctcatgtacaggtat      1                661710     230
  MS65          tgctcaattcccaatacaa     tccatttccttaaccacatc      1                829293     251
  MS66          ctaccactatcaccggtagc    catcagcgttacttgcatc       1                1502024    266
  MS67          ctcgtttagaaaagccagaa    gtctctttatcagcagcttca     1                1676770    245
  MS68          tcacatcgggtaacaagaa     tatttatcgaccccaaactg      1                1919116    469
  MS69          atgtgtacagcaatcaacga    catctgaagactcctccaaa      1                1977213    245
  MS70          actcatttgcaccgtatctt    aactctggaatctcaaccaa      1                2420234    227
  MS71          aggtggttaggaccattagg    gttgttgattcagaggttcc      2                1623       252
  MS72          ttcacaatgaattctgagga    aaatttcattgcttgatttga     2                184360     230
  MS73          tccttgtggttcaagtaaaac   caaaacctcacttcaccttt      2                906540     257
  MS74          gactctggaggggaaaga      gtgttaaccacgggaaaag       2                1070539    246
  MS75          ccaccccgtctactatatca    ttcacacaacgcttcttaaa      2                1278718    244
  MS76          ggtgtgcacttaagcagttt    tgaaggacttttcacacaaat     2                1378981    253
  MS77          ggtaaccaacaaccacattt    tgcttatgaactcaatcatctc    2                1555168    270
  MS78          caaccaatctactcccaact    tggatattccaatcgattattag   2                1739970    361

The amplicon sizes shown are those found in the *T. parva* Muguga clone 3308 ([http://www.tigr.org](http://www.tigr.org/)).
